CoChat

Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: The role of atenolol in the management of patients with hypertension is currently under scrutiny. Our aim was to evaluate the real-world consequences of recent clinical trial findings. METHODS: We conducted a retrospective, cohort study using linked administrative data from the province of Saskatchewan, Canada. Eligible subjects were first-ever users of antihypertensive medications between 1 January 1994 and 31 December 2003 and were grouped into four cohorts: atenolol, angiotensin-converting enzyme inhibitors (ACEI), thiazide diuretics, or calcium antagonists. Patients remained eligible during monotherapy only. RESULTS: We identified 19 249 eligible individuals (mean age 60.6 years) who were followed for a mean of 2.3 years (SD 2.0). The rate of myocardial infarction, unstable angina, stroke, or death occurred in similar frequencies among all cohorts: atenolol (2.3%), ACEI (3.6%), thiazide diuretics (2.9%), and calcium antagonists (3.9%). After adjustment for potential confounders, atenolol therapy was not associated with higher event rates than the other first-line agents, with hazard ratios ranging between 1.03 [95% confidence intervals (CI) 0.72-1.46] and 1.24 (95% CI 0.91-1.68) for all cohorts compared with atenolol. Similar results were observed upon stratifying the sample into subjects above and below 60 years of age. CONCLUSION: The low event rates for all cohorts suggest that atenolol has not been associated with a significant burden of cardiovascular morbidity or mortality in its traditional role for uncomplicated hypertension. Further study is needed to identify the specific types of patients that should avoid atenolol as an antihypertensive agent.

Overview

Integrity signals

Registry

Crossref · 10.1097/hjh.0b013e328136bd21

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 16 references

Cited by

See all 39

Metadata

Authors
Blackburn, D. F., Lamb, D. A., Eurich, D. T., Johnson, J. A., Wilson, T. W., Dobson, R. T., & Blackburn, J. L.
Affiliations
  • University of Saskatchewan (CA)
  • University of Alberta (CA)
Corresponding author
  • Blackburn, David F
  • Blackburn, James L
Venue
Journal of Hypertension
Published
2007-07
Volume
25
Issue
7
Pages
1499-1505
ISSN
0263-6352 (ISSN-L)
OpenAlex
W2011861015
Cited by
39
References
16
Citations by year
2024: 1 · 2022: 1 · 2020: 1 · 2019: 1 · 2017: 1 · 2016: 2 · 2014: 4 · 2013: 1 · 2012: 9
FWCI
3.51
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Hypertension (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
Keywords
atenolol, hypertension, first-line antihypertensive therapy, beta-blockers, ACE inhibitors, thiazide diuretics, calcium channel blockers, cardiovascular morbidity, cardiovascular mortality, real-world outcomes, linked administrative data
MeSH terms
Adrenergic beta-Antagonists, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Atenolol, Calcium Channel Blockers, Canada, Cardiovascular Diseases, Humans, Hypertension, Retrospective Studies, Cohort Studies, Survival Rate, Odds Ratio, Databases, Factual, Sodium Chloride Symporter Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents. https://app.cochat.ai/papers/10.1097/hjh.0b013e328136bd21
The paper
Blackburn, D. F., Lamb, D. A., Eurich, D. T., Johnson, J. A., Wilson, T. W., Dobson, R. T., & Blackburn, J. L. (2007). Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents. Journal of Hypertension. https://doi.org/10.1097/hjh.0b013e328136bd21

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.